Vol. 3 No. 7 (2023)
Reimbursement Reviews

Nivolumab (Opdivo)

Published July 11, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses nivolumab (Opdivo), 360 mg intravenously, every 3 weeks for up to 3 cycles.
  • Indication: In combination with platinum-doublet chemotherapy for the neoadjuvant treatment of adult patients with resectable non–small cell lung cancer (tumours ≥ 4 cm or node-positive).